Why semaglutide is a useful case study for peptide impurity comparability, analytical characterization and immunogenicity assessment.
Semaglutide is a useful regulatory example because FDA product-specific guidance illustrates the growing use of comparative characterization for synthetic peptide products and their impurity profiles.
Reference-product comparison
The proposed product and reference product are compared across identity, structural attributes and impurity profiles.
Multiple lots
Comparability should reflect normal product variability rather than one isolated batch.
Impurity profile
New or higher peptide-related impurities can require additional justification, especially when they could alter immunogenicity.
Beyond concentration alone
The significance of an impurity depends on sequence/structure and immunogenicity evidence as well as its measured level.
Frequently asked questions
Why is semaglutide relevant to impurity qualification?
It is a prominent peptide product with specific FDA comparability guidance.
Is the semaglutide approach automatically transferable to all peptides?
No. FDA uses product-specific guidance.
Do impurity levels alone determine acceptability?
No.
Can comparative immunogenicity evidence be important?
Yes.
